• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan+
  • Wellness
  • Classicsâ„¢+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Career
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan+
  • Wellness
  • Classicsâ„¢+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Career
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Once-a-month fitusiran reduces bleeding rates in patients with hemophilia A and B with inhibitors

byNeel MistryandTeddy Guo
May 16, 2023
in Chronic Disease, Hematology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Annualized bleeding rate was reduced by 91% in the fitusiran prophylaxis group compared to the bypassing agents on-demand group.

2. 5% of patients in the fitusiran group reported thromboembolic events; there were no deaths.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Hemophilia is marked by a deficiency in certain coagulation factors that make patients prone to bleeding. Prophylaxis is the standard of care in these patients but is often complicated by the need for frequent transfusions and loss of intravenous access. Fitusiran is a novel small interfering RNA that may regulate hemostasis through the inhibition of antithrombin synthesis, although its use in hemophilia patients is not well known. This randomized controlled trial aimed to compare the safety and efficacy of fitusiran in patients with hemophilia A and hemophilia B with inhibitors. The primary outcome was the mean annualized bleeding rate while key secondary outcomes included joint and spontaneous bleeding rate and mobility concerns. According to study results, patients in the fitusiran group reported significantly reduced bleeding events and greater hemostatic efficacy compared to the bypassing agents on-demand group. Although this study was well done, it included a small sample size with a 2:1 randomization in favor of the intervention group. Additionally, excluding patients with less than 60% antithrombin activity may reduce the generalizability of these results to other patients with hemophilia.

Click to read the study in The Lancet

Relevant Reading: Efanesoctocog Alfa Prophylaxis for Patients with Severe Hemophilia A

RELATED REPORTS

Thalidomide reduces recurrent bleeding from small-intestinal angiodysplasia

Extracorporeal membrane oxygenation increases bleeding risk in patients with cardiogenic shock

Edoxaban does not improve outcomes in patients with atrial high-rate episodes

In-depth [randomized-controlled trial]: Between Feb 14, 2018, and Jun 23, 2021, 85 patients were screened for eligibility across 26 sites in 12 countries. Included were male patients aged ≥ 12 years with hemophilia A or hemophilia B and ≥ 6 bleeding episodes in the past 6 months. Participants with lower than 60% antithrombin activity were excluded. The primary outcome of mean annualized bleeding was significantly lower in the fitusiran prophylaxis group (1.7, 95% confidence interval [CI] 1.0-2.7) compared to the bypassing agents on-demand group (18.1, 95% CI 10.6-30.8), denoting a 91% reduction in bleeding (p<0.0001). Substantially more patients in the fitusiran group (66%) had zero treated bleeds compared to the latter (5%). The majority of adverse events were mild-to-moderate with elevated liver enzymes in 32% and thromboembolic events in 5% of patients in the fitusiran group. There were no treatment-related fatalities. Findings from this study suggest that prophylaxis with fitusiran significantly reduces bleeding among hemophilia patients and may improve clinical outcomes.

Image: PD

©2023 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: bleedingfitusiranhematologyhemophiliahemophilia AHemophilia Bhemostasismajor bleeding
Previous Post

The Scan by 2 Minute Medicine®: Mammogram Recommendation Changes, COVID Called Off, Canadian Wildfires, and National Nurses Week

Next Post

High-dose corticosteroids increase morbidity and mortality among hypoxic COVID-19 patients

RelatedReports

Study explores effects of daily iron supplementation in 2- to 5-year-olds
Chronic Disease

Thalidomide reduces recurrent bleeding from small-intestinal angiodysplasia

December 5, 2023
Reinnervation of cardiac infarcts decreases subsequent arrhythmia incidence [PreClinical]
Cardiology

Extracorporeal membrane oxygenation increases bleeding risk in patients with cardiogenic shock

October 31, 2023
Blood type correlates with egg reserve in infertile women
Cardiology

Edoxaban does not improve outcomes in patients with atrial high-rate episodes

October 13, 2023
CRISPR-mediated gene activation rescues obesity caused by haploinsufficiency [PreClinical]
Chronic Disease

CRISPR-Cas9 promoting fetal hemoglobin production improves severe sickle cell disease

September 13, 2023
Next Post
Novel coronavirus identified from patients with pneumonia in Wuhan, China

High-dose corticosteroids increase morbidity and mortality among hypoxic COVID-19 patients

Female incontinence associated with physical activity

Wellness Check: Exercise

The 2 Minute Medicine Podcast Episode 15

The 2 Minute Medicine Podcast Episode 15

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Seriesâ„¢ textbook.

Subscription Options

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Specific viruses may be associated with increased risk and worse outcomes of ovarian cancer
  • Low-dose amitriptyline effective and well-tolerated for management of irritable bowel syndrome
  • Patisiran prevents functional decline in patients with cardiac amyloidosis
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classicsâ„¢
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Career
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options